ObvioHealth commercializes software solutions to help healthcare industry players substantiate health claims. ObvioHealth’s proprietary digital platform, ClaimIt, utilizes a mobile app interface to execute clinical trials. It removes the costly overhead of physical site visits and brings clinical trials directly to the mobile device of each subject.
Fibronostics is a discovery platform developing non-invasive, algorithm-based diagnostics to improve treatment outcomes, facilitate screening of specific diseases and help prognosis in various chronic conditions. Fibronostics currently focuses on liver disease, identifying high-risk patients and early detection through two products, LiverFast Select and LiverFast.
Evid Science utilizes a well-developed cutting edge Artificial Intelligence to ensure our customers have timely access to the most up-to-date medical evidence, enabling them to stay ahead of the competition, make more informed decisions, and always remain up-to-date on the latest scientific trends. The Evid Science platform puts outcomes evidence at your fingertips. Do in seconds what used to take weeks or even months of manual work. Our tool powers more efficient and cost-effective evidence based decision-making across the enterprise.
RegAsk is a digital platform using natural language processing for answering regulatory questions about path-to-market and path-to-claims for product expansions into foreign markets. RegAsk is backed by a team of regulatory experts with a global perspective and years of navigating some of the most complicated regulatory hurdles in markets big and small.
Travecta Therapeutics develops novel chemistry for delivery of therapies to the brain. Travecta leverages a discovery platform to identify, simplify and categorize small molecules for enabling their transport across the blood-brain barrier. Travecta is based on the research of Professor David Silver at Duke-NUS.
Vanteres is an innovative biotech company committed to the science-based development of lipid nutraceuticals for improving human health. Vanteres leverages its biomedical research expertise to develop actively transported lysophospholipids (ATLs) for a wide range of disease states. The company’s lead ATL is a lysophosphatidylcholine containing essential omega-3 fatty acids or Active-DHA. Active-DHA plays a critical role in the health and maintenance of multiple organs including brain, eye, and liver.
Raffiné is a proprietary e-commerce platform for Japan. It focuses solely on skin and hair care products that deliver tangible outcomes. Raffiné owns brand such as Jeune Vie and licenses from the French cosmetic leader Eugene Perma. Raffiné is headquartered in Tokyo.
Objective GI’s mission is to improve patient care outcomes through clinical research. We understand the importance of developing better solutions to manage silent chronic illnesses such as fatty liver disease. Objective GI establishes partnerships with gastroenterology medical practices providing research infrastructure, optimal trial selection, study implementation, and key personnel management. Our proprietary processes and technology eliminate the healthcare workflow disruptions typically associated with clinical trials.
1nHealth is a digital platform designed to accelerate the advancement of health through subject recruitment innovation, matching the right patients to the right trial at the right time. The technology has been made possible via the deployment of custom built algorithm, which leverages disparate data from several sources to form a total picture, allowing us to target and qualify high potential subjects no one is soliciting using a simple premise: conventional subject targeting delivers subpar, conventional enrollment.